Methods for Continuous IRP Monitoring in Patients With Urinary Stones

Experts converse on the evolving methods for real-time intra-renal pressure monitoring, its benefits in improving surgical procedures, and the potential for future automated adjustments based on the monitored data.

EP: 1.Overview of the Incidence, Diagnosis, and Treatment of Urinary Stones

EP: 2.The Evolving Role of Ureteroscopy in the Treatment of Urinary Stones

EP: 3.Overview of Intrarenal Pressure (IRP)

EP: 4.Potential Complications Seen in Patients With Elevated IRP

EP: 5.Strategies for Reducing Risk of Elevated IRP

EP: 6.Key Treatment and Outcome Data for Patients Undergoing Therapy with Assistance of Ureteral Access Sheaths (UASs)

EP: 7.Factors for Consideration When Employing UASs In Patients With Urinary Stones

Now Viewing

EP: 8.Methods for Continuous IRP Monitoring in Patients With Urinary Stones

EP: 9.Future Perspectives in the Treatment of Patients With Urinary Stones

Related Videos

Related Content

Advertisement

March 21st 2025

FDA reports Urgent Device Field Correction notice for CVAC Aspiration System

Hannah Clarke

Calyxo has identified a new risk of injury when the CVAC System is used in patients with high viscosity fluid in their kidneys at the start of the procedure.

February 17th 2022

Why kidney stones will become more prevalent over time

Urology Times staff

“The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.

March 17th 2025

Kidney stone prevalence is increasing in women, study findings show

Hannah Clarke

The overall prevalence of kidney stones remained stable, with a notable increase observed among women.

September 9th 2021

Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters

Urology Times staff

“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.

February 25th 2025

YOLT-203 shows promise in early phase 1 trial for primary hyperoxaluria 1

Hannah Clarke

YOLT-203 was granted an Orphan Drug Designation and a Rare Pediatric Disease Designation in September 2024.

February 5th 2025

FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1

Hannah Clarke

A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.

Related Content

Advertisement

March 21st 2025

FDA reports Urgent Device Field Correction notice for CVAC Aspiration System

Hannah Clarke

Calyxo has identified a new risk of injury when the CVAC System is used in patients with high viscosity fluid in their kidneys at the start of the procedure.

February 17th 2022

Why kidney stones will become more prevalent over time

Urology Times staff

“The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.

March 17th 2025

Kidney stone prevalence is increasing in women, study findings show

Hannah Clarke

The overall prevalence of kidney stones remained stable, with a notable increase observed among women.

September 9th 2021

Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters

Urology Times staff

“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.

February 25th 2025

YOLT-203 shows promise in early phase 1 trial for primary hyperoxaluria 1

Hannah Clarke

YOLT-203 was granted an Orphan Drug Designation and a Rare Pediatric Disease Designation in September 2024.

February 5th 2025

FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1

Hannah Clarke

A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.